MITO23

Trial Description: 
Randomized phase III trial on Trabectedin (ET 743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients
Lead Cooperative Group: 
Participating Groups: 
Disease Site: 
Ovarian
Trial Status: 
Recruiting
Contact person: